News - Novartis

Filter

Current filters:

Novartis

Popular Filters

201 to 225 of 384 results

News briefs from Sanofi, Biogen/SOBI and Novartis

01-11-2012

French drug major Sanofi (Euronext: SAN) and subsidiary Genzyme have reported results from pivotal studies…

AgrippalBiogen IdecBiotechnologyFluadLemtradaNeurologicalNovartisPharmaceuticalRegulationResearchSanofiSwedish Orphan BiovitrumVaccines

Novartis' flu vaccines suspended in several countries on suspected quality issues

29-10-2012

A number of European Union member states have halted the use, as a precautionary measure, of some anti-influenza…

AgrifluAgrippalEuropeFluadMarkets & MarketingNorth AmericaNovartisPharmaceuticalRegulationVaccines

FDA approves Teva's Synribo for CML; Novartis plans for Tasigna switch

29-10-2012

The US Food and Drug Administration on Friday approved Israel-headquartered Teva Pharmaceutical Industries'…

GleevecNorth AmericaNovartisOncologyPatentsPharmaceuticalRegulationResearchSynriboTasignaTeva Pharmaceutical Industries

Access to many more medicines in Australia, as PBS list extended

28-10-2012

More than 110,000 Australians will benefit from better access to affordable medicines following the Australian…

Asia-PacificBayerEyleaMyforticNovartisPharmaceuticalPricingRegulation

Novartis sales in third-quarter 2012 disappoint; EPS in line

25-10-2012

Swiss drug major Novartis (NOVN: VX) reported third-quarter 2012, showing that net sales reached $13.8…

FinancialNovartisPharmaceutical

US FTC puts divestment conditions on Watson's acquisition of Actavis

16-10-2012

The USA's Federal Trade Commission will require Watson Pharmaceuticals (NYSE: WPI) and fellow generic…

ActavisGenericsLegalMergers & AcquisitionsNorth AmericaNovartisPar PharmaceuticalsSandozWatson Pharmaceuticals

Highlights from ECTRIMS include new data for Gilenya, Sativex and Aubagio

14-10-2012

New data presented at the 28th congress of the European Committee for Treatment and Research in Multiple…

AlmirallAubagioBiotechnologyGenzymeGilenyaGW PharmaceuticalsNeurologicalNovartisPharmaceuticalResearchSanofiSativex

Overview of Novartis' patent losses from GlobalData

11-10-2012

Swiss drug major Novartis (NOVN: VX) is the latest victim of patent protection loss, note analysts at…

DiovanFemaraFinancialGleevecNovartisPatentsPharmaceuticalReclastZometa

UK's NICE draft guidance backs NHS use of Lucentis in DME

05-10-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in new draft guidance…

BiotechnologyEuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

"Sandoz will be the leading biosimilars company in 2012," says Visiongain

04-10-2012

Sandoz, the generics unit of Swiss drug major Novartis (NVN: VX), will retain its position as the global…

BiotechnologyDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingNovartisSandoz

Novartis criticizes system of public procurement tenders in Russia

28-09-2012

Amid the ever growing competition in the Russian pharmaceutical market, the world's largest pharmaceutical…

EuropeNovartisPharmaceuticalPricingRegulation

Novartis' secukinumab significantly effective in hard-to-treat plaque psoriasis

27-09-2012

September 27, 2012 Swiss drug major Novartis (NOVN: VX) this morning announced new Phase II data…

AIN457DermatologicalsNovartisPharmaceuticalResearchsecukinumab

Novartis' serelaxin reduces mortality in AHF patients

25-09-2012

Phase III study results released by Swiss drug major Novartis (NOVN: VX) yesterday show that its investigational…

Cardio-vascularNovartisPharmaceuticalRelaxinResearchRLX030serelaxin

Mylan debuts first generic Diovan HCT and Antivert copy in USA

23-09-2012

US generic drugmaker Mylan (Nasdaq: MYL) last Friday received final approval from the US Food and Drug…

AntivertCardio-vascularDiovan HCTGenericsMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaNovartisPfizerRegulation

Playing ball with Russia in the pharma sector

16-09-2012

Commenting on last week's announcement that Takeda Pharmaceuticals (TYO: 4502) had completed its $96…

EuropeNovartisPharmaceuticalPoliticsProductionTakeda PharmaceuticalsTeva Pharmaceutical Industries

India's patent laws under pressure, say UK researchers

11-09-2012

In a special report in the prestigious medical journal The Lancet, researchers from Queen Mary, University…

Asia-PacificBayerEuropeGenericsLegalNovartisPatentsPharmaceutical

Scotland denies access to Roche skin cancer drug Zelboraf, but OKs Novartis' Gilenya

11-09-2012

Swiss drug major Roche (ROG SIX) says it is "extremely disappointed" that the Scottish Medicines Consortium…

EuropeGilenyaHealthcareNeurologicalNovartisOncologyPharmaceuticalPricingRegulationRocheZelboraf

Safety of Novartis' Lucentis in VI-DME confirmed with new data; efficacy in CNV

06-09-2012

New data revealed yesterday by Swiss drug major Novartis (NOVN: VX) showed that Lucentis (ranibizumab)…

DiabetesLucentisNovartisOphthalmicsPharmaceuticalRegulationResearchRoche

201 to 225 of 384 results

Company Spotlight

Fibrotech

Fibrotech

Back to top